<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641472</url>
  </required_header>
  <id_info>
    <org_study_id>DX-RES-2103</org_study_id>
    <secondary_id>D5257L00750</secondary_id>
    <nct_id>NCT00641472</nct_id>
  </id_info>
  <brief_title>Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children</brief_title>
  <official_title>An Evaluation of the Effectiveness of Pulmicort Respules (Budesonide Inhalation Suspension) Versus SINGULAIR (Montelukast Sodium) in Children 2-8 Years Old With Asthma Requiring Controller Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A one year study comparing the safety and effectiveness of Pulmicort (0.5mg strength given
      once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the
      evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children
      aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will
      receive 5mg strength SINGULAR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first asthma medication as either step-up PULMICORT RESPULES or oral steroids</measure>
    <time_frame>Each clinic visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>Each clinic visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1st additional asthma medication measured at 12 weeks and 26 weeks</measure>
    <time_frame>Each clinic visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 1st acute severe exacerbation (as measured by the need for oral steroids), measured at 12 weeks, 26 weeks, and 52 weeks</measure>
    <time_frame>Each clinic visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide inhalation suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Montelukast sodium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide inhalation suspension</intervention_name>
    <description>0.5mg</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pulmicort Respules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast Sodium</intervention_name>
    <description>4mg or 5mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>SINGULAR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2 to 8 at study entry

          -  At least 3 episodes of wheezing in the previous year that lasted more than 24 hours
             and affected sleep or symptoms of mild persistent asthma

          -  use of b-2 agonist treatment on at least 3 of 7 consecutive days or run in

        Exclusion Criteria:

          -  Severe or unstable asthma

          -  any significant finding at a physical exam

          -  an exacerbation of asthma in the 30 days before entering the study that might affect
             study results in judgement of the study doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertil Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>March 24, 2009</last_update_submitted>
  <last_update_submitted_qc>March 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Lars-GÃ¶ran Carlsson</name_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Pulmicort</keyword>
  <keyword>Children</keyword>
  <keyword>paediatrics</keyword>
  <keyword>budesonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

